解放军总医院发布CAR-T疗法 I期临床数据

2015-05-27 佚名 生物探索

近日,Cellular Biomedicine Group宣布了其CAR-T CD30霍奇金淋巴瘤免疫-肿瘤研发项目令人振奋的I期临床数据。7名患者中有5人对CAR-CD30 T细胞疗法有应答,且该疗法被证明安全、可行、有效。 该试验由中国解放军总医院设计并执行,项目主要负责人是该院癌症免疫治疗部门的主任韩卫东教授。该研究招募的患者具有严重的治疗历史和/或多个肿瘤病变却没有可用的


近日,Cellular Biomedicine Group宣布了其CAR-T CD30霍奇金淋巴瘤免疫-肿瘤研发项目令人振奋的I期临床数据。7名患者中有5人对CAR-CD30 T细胞疗法有应答,且该疗法被证明安全、可行、有效。

该试验由中国解放军总医院设计并执行,项目主要负责人是该院癌症免疫治疗部门的主任韩卫东教授。该研究招募的患者具有严重的治疗历史和/或多个肿瘤病变却没有可用的治疗方案,即现在的疗法下只有有限的预后(several months to < 2 year survival)。

7名患有复发/难治性霍奇金淋巴瘤的患者参加了CAR-CD30 T细胞疗法试验,其中2人获得部分缓解,3人获得疾病稳定(stable disease ,SD),因此,该疗法整体疾病控制率为71.4%(5/7);客观缓解率为28.6% (2/7)。此外,此疗法对其中1人产生了副作用,细胞回输2周后产生了5天的self-limiting关节痛、肌痛和双膝肿胀。

5月21日,在英国伦敦举行的第十届世界干细胞与再生医学大会,Cellular Biomedicine Group的首席执行官William (Wei) Cao公布了这些数据。他说:“CAR-T CD30技术的有效性和安全性数据让我们备受鼓舞。”

不久前, Wei (William)Cao还在Regen医学投资者大会上公布了该公司另外两种CAR-T细胞疗法的I期临床结果。CAR-CD19 T实验招募了9个复发或化疗难治性B细胞急性淋巴细胞白血病(ALL)的成人患者。结果发现22.2%的患者(2/9)表现完全缓解和44.4%的患者(4/9)显示部分缓解,总缓解率为66.7%(6/9)。

CAR-CD20 T实验有7例化疗难治性,晚期弥漫性大B细胞淋巴瘤(DLBCL)患者参与,其中2个含有大块肿瘤患者当中的1个经CAR-CD20T细胞治疗后在14个月内显示完全缓解,另一例6个月内表现部分缓解。4个有效大块肿瘤负荷病例当中的3个治疗后取得3至6个月缓解,总应答率75%(3/4)。


Cellular Biomedicine Group产品线


Cellular Biomedicine Group是一家在纳斯达克上市的致力于研发治疗退行性疾病和癌症细胞疗法的公司。2月9日,该公司收购了中国解放军总医院的CAR-T细胞疗法,这项收购包括CD19、CD20、CD30、以及人表皮生长因子受体(EGFR)重组表达载体等免疫技术,已有的临床I/II期结果、相关专利的所有权、以及生产技术。

Wei (William)Cao表示,公司希望能够在今年的第三季度公布EGFR-HER1-阳性晚期肺癌试验的临床数据,并获得Immuno-Oncology平台中其它项目的进一步进展。

原始出处:

Cellular Biomedicine Group Announces Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016689, encodeId=5bbf2016689dc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jun 01 14:17:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652727, encodeId=fc741652e27a0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:17:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781080, encodeId=7be81e8108098, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 27 02:17:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764089, encodeId=9c931e64089e2, content=<a href='/topic/show?id=d76d9102e83' target=_blank style='color:#2F92EE;'>#解放军总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91027, encryptionId=d76d9102e83, topicName=解放军总医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5837624055, createdName=12498b08m102暂无昵称, createdTime=Sun Aug 02 12:17:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923442, encodeId=608a19234427a, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Mon Jul 13 08:17:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25602, encodeId=04ec25602c2, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:23:00 CST 2015, time=2015-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016689, encodeId=5bbf2016689dc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jun 01 14:17:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652727, encodeId=fc741652e27a0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:17:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781080, encodeId=7be81e8108098, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 27 02:17:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764089, encodeId=9c931e64089e2, content=<a href='/topic/show?id=d76d9102e83' target=_blank style='color:#2F92EE;'>#解放军总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91027, encryptionId=d76d9102e83, topicName=解放军总医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5837624055, createdName=12498b08m102暂无昵称, createdTime=Sun Aug 02 12:17:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923442, encodeId=608a19234427a, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Mon Jul 13 08:17:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25602, encodeId=04ec25602c2, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:23:00 CST 2015, time=2015-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2016689, encodeId=5bbf2016689dc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jun 01 14:17:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652727, encodeId=fc741652e27a0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:17:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781080, encodeId=7be81e8108098, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 27 02:17:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764089, encodeId=9c931e64089e2, content=<a href='/topic/show?id=d76d9102e83' target=_blank style='color:#2F92EE;'>#解放军总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91027, encryptionId=d76d9102e83, topicName=解放军总医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5837624055, createdName=12498b08m102暂无昵称, createdTime=Sun Aug 02 12:17:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923442, encodeId=608a19234427a, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Mon Jul 13 08:17:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25602, encodeId=04ec25602c2, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:23:00 CST 2015, time=2015-05-31, status=1, ipAttribution=)]
    2015-08-27 仁者大医
  4. [GetPortalCommentsPageByObjectIdResponse(id=2016689, encodeId=5bbf2016689dc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jun 01 14:17:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652727, encodeId=fc741652e27a0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:17:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781080, encodeId=7be81e8108098, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 27 02:17:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764089, encodeId=9c931e64089e2, content=<a href='/topic/show?id=d76d9102e83' target=_blank style='color:#2F92EE;'>#解放军总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91027, encryptionId=d76d9102e83, topicName=解放军总医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5837624055, createdName=12498b08m102暂无昵称, createdTime=Sun Aug 02 12:17:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923442, encodeId=608a19234427a, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Mon Jul 13 08:17:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25602, encodeId=04ec25602c2, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:23:00 CST 2015, time=2015-05-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2016689, encodeId=5bbf2016689dc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jun 01 14:17:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652727, encodeId=fc741652e27a0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:17:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781080, encodeId=7be81e8108098, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 27 02:17:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764089, encodeId=9c931e64089e2, content=<a href='/topic/show?id=d76d9102e83' target=_blank style='color:#2F92EE;'>#解放军总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91027, encryptionId=d76d9102e83, topicName=解放军总医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5837624055, createdName=12498b08m102暂无昵称, createdTime=Sun Aug 02 12:17:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923442, encodeId=608a19234427a, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Mon Jul 13 08:17:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25602, encodeId=04ec25602c2, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:23:00 CST 2015, time=2015-05-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2016689, encodeId=5bbf2016689dc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jun 01 14:17:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652727, encodeId=fc741652e27a0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:17:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781080, encodeId=7be81e8108098, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 27 02:17:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764089, encodeId=9c931e64089e2, content=<a href='/topic/show?id=d76d9102e83' target=_blank style='color:#2F92EE;'>#解放军总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91027, encryptionId=d76d9102e83, topicName=解放军总医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5837624055, createdName=12498b08m102暂无昵称, createdTime=Sun Aug 02 12:17:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923442, encodeId=608a19234427a, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Mon Jul 13 08:17:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25602, encodeId=04ec25602c2, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:23:00 CST 2015, time=2015-05-31, status=1, ipAttribution=)]
    2015-05-31 huaxipanxing

    看看

    0

相关资讯

CAR-T细胞治疗非霍奇金氏淋巴瘤经历“阿喀琉斯之踵”

最近由美国斯隆-凯特琳癌症中心主导的一项关于利用重组T细胞治疗非霍奇金氏淋巴瘤的早期研究因出现患者死亡事件而被迫暂停。主要原因是进行CAR-T细胞治疗过程中,细胞因子释放综合征[CRS]所致。 两周以前MSK向总部位于圣迭戈的美国癌症研究学会通报了两名患者在研究中死亡的情况,并作出上述决定以重新审视这一疗法的安全性。两名患者在接受了经过CAR-T(嵌合抗原受体改造后的T细胞)移植后两

竞争白热化!强生与Transposagen签订合作协议宣布进入CAR-T研究领域

随着医疗技术的发展,人类已经征服了无数种过去认为是不治之症的疾病,天花等疾病也已经从人类社会彻底销声匿迹。然而癌症仍然是横亘在人类改善健康状况提高生活质量的道路上的庞然大物。 近些年来,相关癌症治疗方向已经由最早的化疗和放疗方法发展为利用人体自身免疫系统识别来杀灭肿瘤细胞。今年以来,癌症免疫领域最令人瞩目的就是诺华等公司率先提出的嵌合抗原受体-T细胞(CAR-T)疗法。 而最近强生公司终于

CAR-T免疫疗法,治愈癌症不是梦

今年6月,只有19名员工的KITE生物技术公司在美国纳斯达克上市,一天之内狂揽1亿3千万美金!仅仅过了两个月,同样不到20人的JUNO生物技术公司对外宣布,成功一次性融资1亿3千万美金,这样JUNO一年之内已经融资超过3亿! 这两个小公司没有任何收入,没有一个上市的药物,凭什么如此受投资人的欢迎,而纷纷向它们送钱?因为它们掌握了一项技术,一项叫CAR-T的技术,一个也许能

肿瘤Car-T免疫细胞治疗JCAR015获FDA突破性疗法认定

嵌合抗原受体-T细胞(CAR-T)疗法代表着当今最先进的肿瘤免疫细胞治疗技术,在相关临床试验中取得了巨大的成功,该领域已成为药品研发最热门的领域之一,也是投资合作的大热点。 目前,在CAR-T免疫疗法领域,诺华(Novartis)处于领先地位,其临床试验中有用于白血病、淋巴瘤、间皮瘤和胰腺癌的实验性产品。今年7月,FDA已授予诺华CAR-T免疫疗法CTL019突破性疗法认定。截至目前,诺华凭借出

深度完整版:CAR-T的现状和未来

CAR-T(T细胞嵌合抗原受体)作为一种免疫细胞治疗方案,在全球范围内吸引了包括学者、医生、患者、投资人的大量关注。然而CAR-T具体是什么,它的背后有什么样的故事、目前的研究状况如何,未来又将走向何方呢? CAR-T带来的新曙光 自古以来,人们不断地与癌症进行斗争。科学家们考古发现的木乃伊是死于癌症,敬爱的周总理死于癌症,报纸杂志中风光无限的水果总裁死于癌症,电视剧中美丽的女主角患上